Evaluation of G3BP1 in the prognosis of acute and acute-on-chronic liver failure after the treatment of artificial liver support system

Table 3 Multivariable Cox regression analyses of biomarkers for predicting the risk for progression in training cohort

Biomarker	G3BP1 cut points	Progression (%)	Unadjusted HR (95%CI)	P value	Model 11	Adjusted HR (95%CI) P value
IL-1β (pg/mL)
T1 IL-1β (n = 122)	≤ 168.0	15 (12.3)	1.0 (Reference)		1.0 (Reference)
T2 IL-1β (n = 122)	> 168.0	58 (47.5)	5.38 (3.03-9.54)	< 0.01	4.27 (2.37-7.67)	< 0.01
IL-18 (pg/mL)
T1 IL-18 (n = 122)	≤ 13.425	38 (31.1)	1.0 (Reference)		1.0 (Reference)
T2 IL-18 (n = 122)	> 13.425	35 (28.7)	0.94 (0.59-1.49)	0.78	0.95 (0.59-1.52)	0.83
TNF-α (pg/mL)
T1 TNF-α (n = 122)	≤ 5.465	46 (37.7)	1.0 (Reference)		1.0 (Reference)
T2 TNF-α (n = 122)	> 5.465	27 (22.1)	0.50 (0.31-0.80)	< 0.01	0.55 (0.34-0.90)	0.02

¹Model 1 adjusts the linear variables lactate dehydrogenase, alpha-fetoprotein.

HR: Hazard ratio; IL: Interlenkin; TNF-α: Tumor necrosis factor-α.